Hancock Jaffe Laboratories Inc (HJLI) Stock Price, Forecast & Analysis
NASDAQ:HJLI
HJLI Key Statistics, Chart & Performance
The current stock price of HJLI is 10.38 null. In the past month the price increased by 33.76%. In the past year, price decreased by -3.67%.
HJLI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HJLI. When comparing the yearly performance of all stocks, HJLI is one of the better performing stocks in the market, outperforming 77.04% of all stocks.
HJLI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HJLI. HJLI has a great financial health rating, but its profitability evaluates not so good.
HJLI Financial Highlights
Over the last trailing twelve months HJLI reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS increased by 48.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.15% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
HJLI Forecast & Estimates
1 analysts have analysed HJLI and the average price target is 26.52 null. This implies a price increase of 155.49% is expected in the next year compared to the current price of 10.38.
HJLI Ownership
HJLI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.41 | 197.518B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.82 | 175.875B | ||
| SYK | STRYKER CORP | 24.2 | 139.086B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.16 | 108.957B | ||
| IDXX | IDEXX LABORATORIES INC | 41.66 | 51.801B | ||
| BDX | BECTON DICKINSON AND CO | 11.28 | 51.46B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.71 | 46.035B | ||
| RMD | RESMED INC | 20.01 | 37.897B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.66 | 36.095B | ||
| DXCM | DEXCOM INC | 25.78 | 26.58B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HJLI
Company Profile
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 19 full-time employees. The company went IPO on 2018-05-31. The firm is engaged in developing tissue based devices that are designed for patients with cardiovascular disease, and peripheral arterial and venous disease. The firm's product includes VenoValve and CoreoGraft. VenoValve is a device surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (CVI). CoreoGraft is a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (CABG) surgeries.
Company Info
Hancock Jaffe Laboratories Inc
70 Doppler
Irvine CALIFORNIA 92618 US
CEO: Robert Berman
Employees: 19
Phone: 19492612900.0
Hancock Jaffe Laboratories Inc / HJLI FAQ
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 19 full-time employees. The company went IPO on 2018-05-31. The firm is engaged in developing tissue based devices that are designed for patients with cardiovascular disease, and peripheral arterial and venous disease. The firm's product includes VenoValve and CoreoGraft. VenoValve is a device surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (CVI). CoreoGraft is a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (CABG) surgeries.
What is the current price of HJLI stock?
The current stock price of HJLI is 10.38 null. The price decreased by -1.98% in the last trading session.
What is the dividend status of Hancock Jaffe Laboratories Inc?
HJLI does not pay a dividend.
What is the ChartMill technical and fundamental rating of HJLI stock?
HJLI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting HJLI stock to perform?
1 analysts have analysed HJLI and the average price target is 26.52 null. This implies a price increase of 155.49% is expected in the next year compared to the current price of 10.38.
How is the valuation of Hancock Jaffe Laboratories Inc (HJLI) based on its PE ratio?
Hancock Jaffe Laboratories Inc (HJLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.47).
Is Hancock Jaffe Laboratories Inc (HJLI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HJLI.